Search - tctmd.com

Displaying 121 - 140 of 319

Sort: Relevancy | Date

News Conference News ACC 2014

NEXT at 2 Years: Nobori DES Still Noninferior to Xience/Promus

Jason Kahn

March 31, 2014

News Daily News

ZES Continue to Match EES in All Comers at 4 Years

March 13, 2014

News Daily News

First-Generation Bioresorbable Stent Performs Well in SFA Lesions

Jason Kahn

February 20, 2014

News Daily News

Meta-analysis: IVUS-Guided Stent Placement Improves Outcomes vs Angiography

L.A. McKeown

February 17, 2014

News Daily News

DAPT Interruption At Least 1 Month After ZES Implantation Appears Safe

Yael L. Maxwell

February 17, 2014

News Daily News

DUTCH PEERS Published: Third-Generation Zotarolimus, Everolimus Stents Equivalent

February 12, 2014

News Daily News

DUTCH PEERS Publicado: Los Stents liberadores de Zotarolimus y Everolimus de 3ª Generación son Equivalentes

February 12, 2014

News Daily News

Stent Malapposition Frequent, But Without Clinical Consequences

Jason Kahn

January 27, 2014

News Daily News

RIBS V Published: Good Outcomes with DEB, EES for BMS In-stent Restenosis Patients

January 22, 2014

News Daily News

Bioresorbable Scaffold Designed for PAD Yields Good Early Results

January 22, 2014

News Daily News

EES Reduce Revascularization vs. BMS Regardless of Kidney Disease Severity

January 09, 2014

News Daily News

Bioresorbable Scaffolds Show Promise in Select STEMI Patients

Yael L. Maxwell

January 09, 2014

News Daily News

Second-Generation DES the Better Choice for STEMI Patients

December 09, 2013

News Daily News

IVUS Guidance Reduces Stent Thrombosis, MACE Compared to Angiography

December 08, 2013

News Conference News TCT 2013

Meta-analysis: Most DES Safer Than BMS, Biodegradability Offers No Extra Benefit

November 03, 2013

Presentation TCT 2013

DUTCH PEERS (TWENTE II): A Prospective, Randomized, "All-Comers" Trial of Third-Generation Zotarolimus-Eluting Stents vs. Everolimus-Eluting Coronary Stents

Presenter: Clemens von Birgelen

October 31, 2013

Presentation TCT 2013

Drug-Eluting Balloons vs. Everolimus-Eluting Stents for Treatment of In-Stent Restenosis

Presenter: J?rg Schr?der

October 31, 2013

News Conference News TCT 2013

DUTCH PEERS: Third-Generation Stents Equivalent, Effective

October 31, 2013

News Industry News

Comparison of Two Third-Generation Drug-Eluting Stents Establishes Comparable Safety and Efficacy; Demonstrates Non-Inferiority of Newest Zotarolimus-Eluting Stent

October 31, 2013

Presentation TCT 2013

RIBS V: A Prospective, Randomized Trial of Paclitaxel Coated Balloon Angioplasty vs. Everolimus-Eluting Stents in Bare Metal In-Stent Restenosis

Presenter: Fernando Alfonso

October 30, 2013

Advertisement

NEXT at 2 Years: Nobori DES Still Noninferior to Xience/Promus

ZES Continue to Match EES in All Comers at 4 Years

First-Generation Bioresorbable Stent Performs Well in SFA Lesions

Meta-analysis: IVUS-Guided Stent Placement Improves Outcomes vs Angiography

DAPT Interruption At Least 1 Month After ZES Implantation Appears Safe

DUTCH PEERS Published: Third-Generation Zotarolimus, Everolimus Stents Equivalent

DUTCH PEERS Publicado: Los Stents liberadores de Zotarolimus y Everolimus de 3ª Generación son Equivalentes

Stent Malapposition Frequent, But Without Clinical Consequences

RIBS V Published: Good Outcomes with DEB, EES for BMS In-stent Restenosis Patients

Bioresorbable Scaffold Designed for PAD Yields Good Early Results

EES Reduce Revascularization vs. BMS Regardless of Kidney Disease Severity

Bioresorbable Scaffolds Show Promise in Select STEMI Patients

Second-Generation DES the Better Choice for STEMI Patients

IVUS Guidance Reduces Stent Thrombosis, MACE Compared to Angiography

Meta-analysis: Most DES Safer Than BMS, Biodegradability Offers No Extra Benefit

DUTCH PEERS (TWENTE II): A Prospective, Randomized, "All-Comers" Trial of Third-Generation Zotarolimus-Eluting Stents vs. Everolimus-Eluting Coronary Stents

Drug-Eluting Balloons vs. Everolimus-Eluting Stents for Treatment of In-Stent Restenosis

DUTCH PEERS: Third-Generation Stents Equivalent, Effective

Comparison of Two Third-Generation Drug-Eluting Stents Establishes Comparable Safety and Efficacy; Demonstrates Non-Inferiority of Newest Zotarolimus-Eluting Stent

RIBS V: A Prospective, Randomized Trial of Paclitaxel Coated Balloon Angioplasty vs. Everolimus-Eluting Stents in Bare Metal In-Stent Restenosis

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content